RECOMBINANT ALPHA INTERFERON IN METASTATIC RENAL-CELL CARCINOMA - A COOPERATIVE PHASE-II STUDY

被引：9

作者：

BONO, AV

BRAUSI, M

REALI, L

VICINI, D

BENVENUTI, C

PAVONEMACALUSO, M

RIGATTI, P

ANSELMO, G

GIBBA, A

COPPI, F

COSCIANICUNICO, S

FRANCH, L

机构：

[1] SAN RAFFAELE HOSP,MILAN,ITALY

[2] CIVIL HOSP,BIELLA,ITALY

[3] CIVIL HOSP,TREVISO,ITALY

[4] CIVIL HOSP,VOGHERA,ITALY

[5] CIVIL HOSP,ZONGONIA,ITALY

[6] CIVIL UNITED HOSP,BRESCIA,ITALY

[7] KAMAZZINI HOSP,CAPRI,ITALY

[8] UNIV MILAN,UROL CLIN,I-20122 MILAN,ITALY

[9] UNIV PALERMO,UROL CLIN,I-90134 PALERMO,ITALY

来源：

UROLOGY | 1991年 / 38卷 / 01期

关键词：

D O I：

10.1016/0090-4295(91)80016-Z

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A total of 61 evaluable patients with advanced renal cell carcinoma have been treated with 3 x 10(6) IU per square meter of body surface with recombinant alpha 2b interferon three times a week within a Cooperative Phase II Study. Toxic death for terminal renal failure occurred in 1 patient (1.63%), and toxicities greater than WHO grade 2 were present in 10 cases (16%). The overall response rate after six months of treatment was 13.1% (partial response 4, minor response 4). Two complete responses were obtained at nine and fifteen months (3.3%). Long-lasting stabilization of disease was 13.1 percent.

引用

页码：60 / 63

页数：4

共 9 条

[1] ANTI-TUMOR EFFECTS OF INTERFERON [J].

GRESSER, I ;

TOVEY, MG .

BIOCHIMICA ET BIOPHYSICA ACTA, 1978, 516 (02) :231-247

[2]

KEMPF RA, 1984, P AN M AM SOC CLIN, V3, P59

[3]

KNIGHT E, 1984, INTERFERON GENERAL A, V1

[4]

NEIDHART JA, 1984, P ASCO, V3, P460

[5] BIOCHEMICAL PATHWAYS IN INTERFERON-ACTION [J].

SEN, GC .

PHARMACOLOGY & THERAPEUTICS, 1984, 24 (02) :235-257

[6]

SWANSON DA, 1987, VICC MONOGRAPH

[7]

TAYLOR JL, 1984, INTERFERON GEN APPL, V1, P140

[8]

UMEDA T, 1986, CANCER, V58, P1231, DOI 10.1002/1097-0142(19860915)58:6<1231::AID-CNCR2820580610>3.0.CO

[9]

2-#

← 1 →